信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

III 信息服务

盘前交易 12-19 08:48:25 EST

5.97

+0.12

+2.05%

最高6.00	最低5.87	成交量22.09万
今开5.90	昨收5.85	日振幅2.21%
总市值2.86亿	流通市值2.04亿	总股本4,788万
成交额131.54万	换手率0.65%	流通股本3,423万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服务","latestPrice":5.97,"timestamp":1766091600000,"preClose":5.85,"halted":0,"volume":220935,"delay":0,"floatShares":34233044,"shares":47884104,"eps":0.190275,"marketStatus":"盘前交易","change":0.12,"latestTime":"12-19 08:48:25 EST","open":5.9,"high":6,"low":5.8706,"amount":1315397.367999,"amplitude":0.02212,"askPrice":6.67,"askSize":100,"bidPrice":5.87,"bidSize":341,"shortable":3,"etf":0,"ttmEps":0.190275,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766154600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":5.97,"dividendRate":0.030151,"postHourTrading":{"tag":"盘后","latestPrice":5.97,"preClose":5.97,"latestTime":"19:33 EST","volume":5141,"amount":30698.77,"timestamp":1766104385390},"volumeRatio":0.5748563475592234,"impliedVol":1.1335,"impliedVolPercentile":0.755},"requestUrl":"/m/hq/s/III/wiki","defaultTab":"wiki","newsList":[{"id":"2592134408","title":"港股异动 | 诺诚健华(09969)涨超4% 自研新型TYK2抑制剂ICP-332治疗CSU获批准开展II/III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2592134408","media":"智通财经","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592134408?lang=zh_cn&edition=full","pubTime":"2025-12-19 11:17","pubTimestamp":1766114258,"startTime":"0","endTime":"0","summary":"消息面上，12月18日，据诺诚健华官微消息，公司宣布，自主研发的新型TYK2抑制剂soficitinib治疗慢性自发性荨麻疹获国家药品监督管理局药品审评中心批准开展II/III期临床试验。Soficitinib是诺诚健华自主研发的高效、高选择性的新型口服TYK2抑制剂，开发用于治疗多种T细胞相关的自身免疫性疾病，目前开发的适应症深度布局皮肤科这一广阔的市场，包括特应性皮炎、白癜风、结节性痒疹、荨麻疹等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","688428","BK4134","III","BK1161","09969","BK0239"],"gpt_icon":0},{"id":"2592973845","title":"新诺威(300765.SZ)子公司司库奇尤单抗注射液III期临床试验获得顶线分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2592973845","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592973845?lang=zh_cn&edition=full","pubTime":"2025-12-18 15:45","pubTimestamp":1766043917,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新诺威 发布公告，公司的控股子公司石药集团巨石生物制药有限公司开发的司库奇尤单抗注射液于近日在III期临床试验中获得顶线分析数据。该产品是巨石生物开发的全人源IgG1单克隆抗体药物，为可善挺的生物类似药。可善挺在中国获批的适应症包括6岁及以上斑块状银屑病、银屑病关节炎、强直性脊柱炎及化脓性汗腺炎，其疗效与安全性已获得广泛认可。有关详细数据将于后续学术会议及期刊上发布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","300765","III","BK0226"],"gpt_icon":0},{"id":"2592902308","title":"III期ARTISTRY-2研究达主要终点，吉利德新型HIV二联疗法展现潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902308","media":"药事纵横","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592902308?lang=zh_cn&edition=full","pubTime":"2025-12-18 07:05","pubTimestamp":1766012717,"startTime":"0","endTime":"0","summary":"12月15日，吉利德宣布III期ARTISTRY-2研究取得积极顶线结果。吉利德计划将ARTISTRY研究的III期结果提交给监管机构，并将在未来的科学大会上公布详细数据。在ARTISTRY-2研究中，每日一次的单片复方方案BIC/LEN达到了主要成功标准，其疗效非劣于BIKTARVY。ARTISTRY-2的研究结果将与III期ARTISTRY-1研究的发现共同构成监管申报的基础。吉利德已于2025年11月公布了ARTISTRY-1的顶线结果，显示BIC/LEN组合耐受性良好，在疗效上非劣于多片式抗反转录病毒治疗方案。目前尚无治愈HIV或艾滋病的方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218071039a6afa5d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218071039a6afa5d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","BK4578","BK4568","LU2089984988.USD","BK4588","IE00B19Z3581.USD","LU0114720955.EUR","LU0320765992.SGD","BK4585","BK4583","LU0234570918.USD","LU0823416689.USD","LU1674673691.USD","SG9999015952.SGD","LU0289739699.SGD","LU1585245621.USD","BK4532","LU0058720904.USD","SG9999015986.USD","LU0882574055.USD","GILD","IE00BSNM7G36.USD","IE0002270589.USD","IE00BZ1G4Q59.USD","IE00B7SZLL34.SGD","BK4134","IE00BKVL7J92.USD","LU1839511570.USD","LU1778281490.HKD","SG9999015945.SGD","BK4550","IE00B3T34201.USD","LU1430594728.SGD","LU2324357040.USD","BK4566","III","LU2468319806.SGD","LU2087621335.USD","BK4139","LU0889565916.HKD","IE00B19Z3B42.SGD","LU1571399168.USD","LU1674673428.USD","LU1066051498.USD","LU1066053197.SGD","SG9999015978.USD"],"gpt_icon":0},{"id":"2591869882","title":"来凯医药-B(02105)：LAE002 (AFURESERTIB)针对HR+/HER2-局部晚期或转移性乳腺癌的III期临床试验(AFFIRM-205)已完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2591869882","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591869882?lang=zh_cn&edition=full","pubTime":"2025-12-15 08:17","pubTimestamp":1765757864,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B 发布公告，集团已完成LAE002联合氟维司群针对治疗HR+/HER2-局部晚期或转移性乳腺癌伴随 PIK3CA/AKT1/PTEN基因改变患者的III期临床试验AFFIRM-205入组。III 期临床试验AFFIRM-205为一项多中心、随机、双盲、安慰剂对照的关键性研究，旨在评估该联合疗法的抗肿瘤疗效及安全性。集团与齐鲁制药有限公司已于 2025年11月12日签订独家许可协议。根据许可协议的条款及条件，齐鲁制药获得在中国地区进行LAE002的研究、开发及商业化的独家许可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4225","BK1161","02105","BK4203","HR","BK4134","III"],"gpt_icon":0},{"id":"2591865967","title":"复星医药控股子公司酮洛芬贴剂获准开展III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2591865967","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591865967?lang=zh_cn&edition=full","pubTime":"2025-12-14 08:13","pubTimestamp":1765671185,"startTime":"0","endTime":"0","summary":"中访网数据 上海复星医药(集团)股份有限公司于2025年12月12日发布公告，其控股子公司上海朝晖药业有限公司研发的酮洛芬贴剂，已获得国家药品监督管理局批准，将在中国境内开展III期临床试验。　　该事件的影响范围主要集中于复星医药集团及其控股子公司朝晖药业的研发管线推进，以及未来潜在的非甾体抗炎药外用贴剂市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251214/31864526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","BK0096","BK1515","02196","BK1593","BK4134","III","BK0183","BK0188","BK0028","BK0196","BK0239","BK0175","BK0012","BK0060","BK0187","600196"],"gpt_icon":0},{"id":"2589352213","title":"中慧生物-B(02627)：冻干人用狂犬病疫苗(人二倍体细胞)的III期临床试验启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2589352213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589352213?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:13","pubTimestamp":1765185186,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B 发布公告，集团近期启动集团冻干人用狂犬病疫苗的III期临床试验。公司于2024年10月完成该在研疫苗的I期临床试验。狂犬病是由一种狂犬病病毒引起的严重病毒性疾病，可能导致意识模糊和渐进性瘫痪等严重症状。利用人二倍体细胞研制的狂犬病疫苗为世卫组织推荐的“金标准”狂犬病疫苗，具有强大的安全性。公司的在研狂犬病疫苗在已完成的I期临床试验中显示出良好的安全性特征。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","02627","BK1161","159646","BK4134"],"gpt_icon":0},{"id":"2589885635","title":"劲方医药-B(02595)：GFH375治疗转移性胰腺癌注册性临床试验在首家研究中心启动 为全球首个口服KRAS G12D抑制剂单药对照化疗III期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2589885635","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589885635?lang=zh_cn&edition=full","pubTime":"2025-12-05 08:16","pubTimestamp":1764893771,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，口服KRAS G12D 抑制剂GFH375治疗经治 KRAS G12D突变型转移性胰腺癌患者的注册性III期试验已在北京大学肿瘤医院启动。这项多中心、开放标签、随机对照的III期试验将在约40家中心开展，计划入组约320例既往接受至少一种标准系统性治疗的转移性胰腺癌患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1161","02595","BK1574","BK1515","09939","BK4134","159938"],"gpt_icon":0},{"id":"2589985521","title":"亚盛医药-B(06855)耐立克®一线治疗Ph+ ALL的全球注册III期临床研究获美国FDA和欧洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589985521","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589985521?lang=zh_cn&edition=full","pubTime":"2025-12-05 08:03","pubTimestamp":1764893004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。同时，耐立克在Ph+ ALL领域深度布局，针对Ph+ ALL领域的治疗已获《CSCO恶性血液病诊疗指南》连续推荐，并获CDE突破性疗法认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2355687059.USD","LU1571399168.USD","LU1699723380.USD","BK4107","III","BK4588","BK1161","BK4081","ALL","06855","BK1574","BK4585","EMA","LU0985320562.USD","BK4139","BK4533","AAPG","BK4134"],"gpt_icon":0},{"id":"2588037958","title":"CSLM Digital Asset Acquisition Corp III, Ltd. (Nasdaq: KOYN) 与 First Digital Group Ltd. 宣布就拟议业务合并签署意向书，以此打造全球稳定币与数字支付领军企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2588037958","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588037958?lang=zh_cn&edition=full","pubTime":"2025-12-02 19:30","pubTimestamp":1764675000,"startTime":"0","endTime":"0","summary":"公司成立于 2019 年，在 2022 年由总部位于直布罗陀的 First Digital Group Ltd. 完成重组。合并后，新公司计划加快 First Digital 的国际扩张速度，拓展其产品组合，并进一步完善其监管与合规体系。顾问 Cohen & Company Capital Markets 担任 First Digital 的独家资本市场及并购顾问。Loeb & Loeb LLP 担任 KOYN 的法律顾问。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3197723/0/zh-hans/CSLM-Digital-Asset-Acquisition-Corp-III-Ltd-Nasdaq-KOYN-%E4%B8%8E-First-Digital-Group-Ltd-%E5%AE%A3%E5%B8%83%E5%B0%B1%E6%8B%9F%E8%AE%AE%E4%B8%9A%E5%8A%A1%E5%90%88%E5%B9%B6%E7%AD%BE%E7%BD%B2%E6%84%8F%E5%90%91%E4%B9%A6-%E4%BB%A5%E6%AD%A4%E6%89%93%E9%80%A0%E5%85%A8%E7%90%83%E7%A8%B3%E5%AE%9A%E5%B8%81%E4%B8%8E%E6%95%B0%E5%AD%97%E6%94%AF%E4%BB%98%E9%A2%86%E5%86%9B%E4%BC%81%E4%B8%9A.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","DAAQU","LU1668664300.SGD","LU1791807156.HKD","LU1861220207.SGD","KOYN","LU2360107671.USD","CSLM","DAAQ","LU1861217088.USD","BK4134","LU0106831901.USD","BK4023"],"gpt_icon":1},{"id":"2588701422","title":"君圣泰医药-B(02511)公布HTD1801与达格列净的头对头III期临床研究结果展现控糖优势及心血管代谢优效获益","url":"https://stock-news.laohu8.com/highlight/detail?id=2588701422","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588701422?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:03","pubTimestamp":1764633831,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君圣泰医药-B 发布公告，HTD1801在2型糖尿病患者中开展的与达格列净头对头的临床III期试验取得了积极的结果，试验达到主要终点，并在多项关键心血管代谢指标的改善上优于达格列净。试验数据再次验证，HTD1801靶向2型糖尿病发生及发展的根源性问题，实现更全面的心血管代谢综合获益。HTD1801具有良好的安全性与耐受性，严重不良事件的发生率为3.8%。君圣泰医药计划于今年内启动HTD1801项目的新药上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02511","III","BK4134"],"gpt_icon":0},{"id":"2586720005","title":"东诚药业(002675.SZ)：氟[18F]思睿肽注射液完成III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2586720005","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586720005?lang=zh_cn&edition=full","pubTime":"2025-11-28 17:27","pubTimestamp":1764322073,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业(002675.SZ)公告，公司控股子公司烟台蓝纳成生物技术股份有限公司(简称“蓝纳成”)正在研发的氟[18F]思睿肽注射液是一种靶向PSMA的放射性体内诊断药物，适用于下述前列腺癌患者前列腺特异性膜抗原(PSMA)阳性病灶的正电子发射断层扫描(PET)成像：拟接受初始根治性治疗，怀疑存在转移灶的前列腺癌患者;血清前列腺特异性抗原(PSA)水平升高，怀疑生化复发的前列腺癌患者。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","BK4134","002675","III"],"gpt_icon":0},{"id":"2586219474","title":"港股异动 | 宜明昂科-B(01541)午后涨超9% IMM0306的III期临床研究方案获CDE许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2586219474","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586219474?lang=zh_cn&edition=full","pubTime":"2025-11-27 13:52","pubTimestamp":1764222736,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B(01541)午后涨超9%，截至发稿，涨7.98%，报7.31港元，成交额1070.04万港元。消息面上，宜明昂科午间公告，公司已获得国家药监局药品审评中心批准IMM0306联合来那度胺治疗复发/难治性滤泡性淋巴瘤的III期临床研究方案，标志着复发/难治性滤泡性淋巴瘤创新疗法的发展加速。据悉，IMM0306是全球首个进入临床阶段的CD47和CD20双靶向双特异性分子，可阻断“别吃我”信号，激活巨噬细胞和NK细胞，优先结合CD20而非CD47，有效消除恶性B细胞，同时将毒性降至最低，从而可改善治疗效果。公司拥有IMM0306的全球知识产权及商业化权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374362.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1223083913.SGD","III","LU1223082519.USD","01541","BK4017","BK1161","BK4134","CDE","LU1223082196.USD"],"gpt_icon":0},{"id":"2586970219","title":"港股异动 | 基石药业-B(02616)现涨超5% 欧盟委员会批准舒格利单抗用于治疗III期非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2586970219","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586970219?lang=zh_cn&edition=full","pubTime":"2025-11-27 13:43","pubTimestamp":1764222201,"startTime":"0","endTime":"0","summary":"消息面上，基石药业宣布，欧盟委员会已批准舒格利单抗的新适应症：单药治疗肿瘤细胞PD-L1表达≥1%、无EGFR敏感突变或ALK、ROS1基因组变异、在含铂放化疗后未出现疾病进展的、不可切除的III期非小细胞肺癌成人患者。基石药业将继续推进舒格利单抗在全球的可及性，践行对患者的长期承诺。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","III","BK1574","02616","BK1161"],"gpt_icon":0},{"id":"2586215237","title":"宜明昂科-B(01541)：药品审评中心批准IMM0306治疗复发╱难治性滤泡性淋巴瘤的III期临床研究方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2586215237","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586215237?lang=zh_cn&edition=full","pubTime":"2025-11-27 12:33","pubTimestamp":1764218031,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 公布，公司已获得国家药品监督管理局药品审评中心批准IMM0306联合来那度胺治疗复发╱难治性滤泡性淋巴瘤的III期临床研究方案，标志着复发╱难治性滤泡性淋巴瘤创新疗法的发展加速。据悉，由该集团独立研发的IMM0306是一种靶向分化簇47及分化簇20 的双特异性分子，是全球首个进入临床阶段的CD47和CD20双靶向双特异性分子。截至本公告日期，该集团拥有IMM0306的全球知识产权及商业化权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374344.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541","BK4134","III"],"gpt_icon":0},{"id":"2586284330","title":"港股异动 | 君实生物(01877)再涨超5% 特瑞普利单抗皮下注射III期临床达主要终点 后续拟申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2586284330","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586284330?lang=zh_cn&edition=full","pubTime":"2025-11-26 11:09","pubTimestamp":1764126584,"startTime":"0","endTime":"0","summary":"消息面上，君实生物宣布，由公司自主研发的特瑞普利单抗注射液对比特瑞普利单抗注射液联合化疗一线治疗复发或转移性非鳞状非小细胞肺癌的多中心、开放、随机对照Ⅲ期临床研究达到主要研究终点。君实生物计划将于近期向监管部门递交该产品的上市许可申请。公开资料显示，JS001sc是公司在已上市产品特瑞普利单抗注射液的基础上开发的皮下注射制剂，为首款进入III期临床研究阶段的国产抗 PD-1 单抗皮下制剂，有望给患者带来用药的便捷性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","688180","III","01877","BK1161","BK1515","BK0239","BK4134"],"gpt_icon":0},{"id":"2586540410","title":"港股异动 | 君实生物(01877)现涨近5% JS001sc肺癌III期临床达主要终点 公司近期将递交上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2586540410","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586540410?lang=zh_cn&edition=full","pubTime":"2025-11-25 10:21","pubTimestamp":1764037296,"startTime":"0","endTime":"0","summary":"消息面上，君实生物宣布，由公司自主研发的特瑞普利单抗注射液对比特瑞普利单抗注射液联合化疗一线治疗复发或转移性非鳞状非小细胞肺癌的多中心、开放、随机对照Ⅲ期临床研究达到主要研究终点。君实生物计划将于近期向监管部门递交该产品的上市许可申请。公告显示，JS001sc是公司在已上市产品特瑞普利单抗注射液的基础上开发的皮下注射制剂，为首款进入III期临床研究阶段的国产抗PD-1单抗皮下制剂，有望给患者带来用药的便捷性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373109.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1161","BK1583","01877","BK4134","III","BK1515","688180"],"gpt_icon":0},{"id":"2584187684","title":"默沙东：发布在研口服PCSK9抑制剂Enlicitide Decanoate的两项III期试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2584187684","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584187684?lang=zh_cn&edition=full","pubTime":"2025-11-20 17:59","pubTimestamp":1763632750,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["SG9999014567.USD","LU0203345920.USD","LU0106261372.USD","LU1430594728.SGD","LU0320765489.SGD","LU0203347892.USD","BK4588","IE0002141913.USD","LU1162221912.USD","BK4559","LU0098860793.USD","IE00B4R5TH58.HKD","LU0965509101.SGD","BK4550","III","LU0320765646.SGD","LU0122379950.USD","LU1066051225.USD","LU1917777945.USD","LU0211331839.USD","LU1585245621.USD","LU1061106388.HKD","LU2023250843.SGD","SG9999013999.USD","IE00B1BXHZ80.USD","SG9999002232.USD","IE00BBT3K403.USD","LU1941712348.USD","LU1116320901.HKD","SG9999015358.SGD","LU2324357040.USD","LU1291159041.SGD","SG9999001176.SGD","LU1699723380.USD","IE00B2B36J28.USD","LU0985320562.USD","LU2106854487.HKD","LU0266013472.USD","MRK","LU1069347547.HKD","SG9999014559.SGD","LU1983299246.USD","IE00BLSP4452.SGD","IE0009355771.USD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","BK4585","LU2461242641.AUD","IE00BN8TJ469.HKD","LU1035773651.USD"],"gpt_icon":0},{"id":"2584900001","title":"港股异动 | 和誉-B(02256)尾盘涨超4% 公司展示匹米替尼临床III期MANEUVER研究长期疗效和安全性数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2584900001","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584900001?lang=zh_cn&edition=full","pubTime":"2025-11-20 14:54","pubTimestamp":1763621660,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B(02256)尾盘涨超4%，截至发稿，涨3.9%，报14.13港元，成交额4541万港元。消息面上，和誉公布，其附属和誉医药在结缔组织肿瘤学会(CTOS)2025年会上以壁报形式，展示匹米替尼(pimicotinib/ABSK021)治疗腱鞘巨细胞瘤(TGCT)患者的全球III期MANEUVER研究的长期疗效、安全性及患者报告结果数据。该长期分析显示，持续接受匹米替尼治疗可为TGCT患者在肿瘤缓解方面带来疗效持续提升与患者报告结果(包括疼痛与功能)的进一步改善，同时维持可接受的安全性，强化匹米替尼在适合患者中的长期应用潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B543WZ88.USD","III","IE00B5MMRT66.SGD","BK1161","IE00BPRC5H50.USD","LU2476274720.SGD","BK4134","02256","LU2778985437.USD","LU2476274308.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"1114967498","title":"信息服务集团第三季度每股收益为0.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1114967498","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114967498?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:28","pubTimestamp":1763569690,"startTime":"0","endTime":"0","summary":"11月3日 - 信息服务集团第三季度营收达到6200万美元，略高于IBES预期的6100万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK4134"],"gpt_icon":0},{"id":"2584605809","title":"百利天恒(688506.SH)：iza-bren用于复发性或转移性食管鳞癌的III期临床试验的期中分析达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2584605809","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584605809?lang=zh_cn&edition=full","pubTime":"2025-11-18 08:23","pubTimestamp":1763425416,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，公司自主研发的全球首创、新概念且唯一进入III期临床阶段的EGFR×HER3双抗ADC在食管鳞癌的III期临床试验中，经独立数据监查委员会判断，在预设的期中分析中达到无进展生存期和总生存期双主要终点，适应症为：既往经PD-1/PD-L1单抗联合含铂化疗治疗失败的复发性或转移性食管鳞癌。这是全球首个ADC药物在食管癌治疗中取得PFS/OS双阳性结果的III期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","02615","91194","BK0239","688506","BK4134"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.isg-one.com","stockEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":0.1615},{"period":"3month","weight":0.1097},{"period":"6month","weight":0.3121},{"period":"1year","weight":0.7663},{"period":"ytd","weight":0.7874}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Information Services Group, Inc.于2006年7月20日在特拉华州注册成立。该公司是一家全球领先的技术研究和咨询公司。ISG是超过900家客户、超过75家百强企业值得信赖的商业伙伴，致力于帮助企业、公共部门组织以及服务和技术提供商实现卓越运营和更快增长。该公司专门从事数字化转型服务，包括自动化、云和数据分析；采购咨询；托管治理和风险服务；网络载体服务；技术战略和运营设计；变革管理；市场情报和技术研究与分析。","yearOnYearQuotes":[{"month":1,"riseRate":0.470588,"avgChangeRate":0.025538},{"month":2,"riseRate":0.529412,"avgChangeRate":0.012941},{"month":3,"riseRate":0.333333,"avgChangeRate":0.043359},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.008159},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.028576},{"month":6,"riseRate":0.5,"avgChangeRate":0.015439},{"month":7,"riseRate":0.444444,"avgChangeRate":0.01427},{"month":8,"riseRate":0.555556,"avgChangeRate":0.010481},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.004212},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.036611},{"month":11,"riseRate":0.611111,"avgChangeRate":0.053419},{"month":12,"riseRate":0.555556,"avgChangeRate":0.005224}],"exchange":"NASDAQ","name":"信息服务","nameEN":"Information"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信息服务,III,信息服务股票,信息服务股票老虎,信息服务股票老虎国际,信息服务行情,信息服务股票行情,信息服务股价,信息服务股市,信息服务股票价格,信息服务股票交易,信息服务股票购买,信息服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}